Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Philippe Calais
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Beta
- 1.26
- Country
- US
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- -1.93
Financials
Net Income
$-6.70MEBITDA
$-6.75MFree Cash Flow
$-5.40MEPS (diluted)
$-7.17Shares Outstanding (diluted)
937.2K+488020.3%Operating Expenses
$6.23MCash & Debt
$8.38MReturn of Capital
$115.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-34.66M | $-52.59 |
| 2024 | $0.00 | $-16.75M | $-47.14 |
| 2023 | $0.00 | $-18.55M | $-3453.65 |
| 2022 | $0.00 | $-17.56M | $-73187.37 |
| 2021 | $0.00 | $-6.84M | $-648.00 |
| 2020 | $0.00 | $-2.34M | $-293.76 |
| 2019 | $0.00 | $-607.2K | $-72.00 |
| 2018 | $0.00 | $-453.4K | $-2359.09 |
Valuation
RNAZhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
130+30.00%Social Signal Score
Mentions (5)
- Newsprnewswire.com·6d ago·Positive
…ight the Phase 1a clinical evaluation of TTX-MC138 in patients with advanced solid tumors BOSTON, Oct. 19, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high risk and advanced cancers, today announced that a poster featuring TTX-MC138, the Company's lead therapeutic candidate, has been accepted and will be presented at the European Society for Medical Oncology (ESMO) Congress 2…
View source ↗ - Newsprnewswire.com·27d ago·Neutral
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors In the 14 efficacy-evaluable patients: 71.4% stable disease rate 57.1% of patients had disease control through three months of therapy 36.7% maintained disease control through six months of therapy Three efficacy-evaluable patients rema
View source ↗ - Newsseekingalpha.com·39d ago·Positive
TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript
View source ↗ - Newsprnewswire.com·45d ago·Neutral
TransCode Therapeutics Announces Leadership Transition Tom Fitzgerald, Chief Financial Officer, Announces his Retirement John Tattory, to become Interim Chief Financial Officer BOSTON, Sept. 10, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the retirement of its Chief Financial Officer, Tom Fitzgerald.
View source ↗ - Newsprnewswire.com·55d ago·Neutral
… of targeting microRNA-10b in bone metastasis with TransCode's lead therapeutic candidate BOSTON, Aug. 31, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a peer-reviewed article in Cancers titled, "Targeting miR-10b in Breast Cancer Bone Colonization Model Using Image-Guided Nucleic Acid-Based Therapeutics." The …
View source ↗
Earnings
Wed, Nov 18(in 3 weeks)
Typical surprise -84.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Apr 15$-18.58 vs $-10.08miss
- Fri, Nov 14$-5.49 vs $-9.24beat
- Thu, Aug 14$-4.94 vs $-8.68beat
- Wed, May 21$-70.28 vs $-2.00miss
- Mon, Apr 7$-8.50 vs $-3.21miss
Estimates and results for RNAZ via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RNAZ officers and directors.
- Bought
- $319k
- Sold
- —
9 trades
0 trades
- Fitzgerald Thomas Abought
- Dudley Robert Michaelbought
- Dudley Robert Michaelbought
- Dudley Robert Michaelbought
- Dudley Robert Michaelbought
- Dudley Robert Michaelbought
- Dudley Robert Michaelboughtdirector, 10 percent owner, officer: Chief Executive Officer·20,000 @ $1.15·$23k·Sep 14, 2022·filing
- Fitzgerald Thomas Abought
46 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RNAZ.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.